Dicerna Pharmaceuticals Inc (DRNA) 18.25 $DRNA
Dicerna Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Business Wire - Fri Apr 18, 3:15PM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that it granted stock options to Pankaj Bhargava, M.D., the Company's chief medical officer, on April 16, 2014, including a stock option to purchase 246,406 shares of common stock of the Company outside of the Company's stockholder approved equity incentive plan. The grant of this stock option was approved by the compensation committee of the board of directors on April 16, 2014 as an inducement material to Dr. Bhargava entering into employment with the Company in reliance on NASDAQ Listing Rule 5635(c)(4). Dr. Bhargava joined the Company as chief medical officer on March 31, 2014. The stock option has an exercise price per share of $16.30, the closing price per share of Company's common stock as reported by NASDAQ on April 16, 2014 and is scheduled to vest over a four-year period, subject to his continued service with the Company. Dr. Bhargava's other compensation information is summarized in a Current Report on Form 8-K previously filed by the Company with the Securities and Exchange Commission.
Dicerna Pharmaceuticals Initiates Phase 1 Study of DCR-MYC in Patients with Solid Tumors and Hematological Malignancies
Business Wire - Wed Apr 16, 3:15PM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced the initiation of a Phase 1 dose-escalating clinical study of DCR-MYC, (also known as DCR-M1711), in patients with solid tumors, multiple myeloma, or lymphoma. DCR-MYC, Dicerna's first drug candidate to enter clinical testing, is a Dicer Substrate siRNA (DsiRNA) that targets the driver oncogene MYC, which is central to the growth of many hematologic and solid tumor malignancies. Dicerna is investigating DCR-MYC in a variety of tumor types with the initial focus on hepatocellular carcinoma.
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Apr 05, 7:10AM CDT
Ugh, ugh, and ugh. Quite a few stocks got hit hard this week, but few like three especially unlucky health-care stocks. April Fools' Day is over, but shareholders of this week's big losers probably still feel like someone is pulling a prank on them....
Is Biotech in a Bubble? The Bear Case Explained
Chris Ahlstrand, The Motley Fool - Motley Fool - Fri Apr 04, 8:30AM CDT
The rumblings of a biotech bubble are getting louder as the Nasdaq Biotech Index has declined about 14% from its peak of $275.40 on February 25th. The recent volatility is a phenomenon that has not been seen in quite some time in the space. So is...
Dicerna Pharmaceuticals names Dr Pankaj Bhargava as CMO
M2 - Thu Apr 03, 5:02AM CDT
RNAi therapeutics company Dicerna Pharmaceuticals (NasdaqGS
RNA) disclosed on Wednesday the addition of Pankaj Bhargava MD, as its chief medical officer.
Hercules Technology Growth Capital Announces Portfolio Update for Q1 2014; Quarter Marked By Continued Portfolio Diversity and Growth and Significant Number of Liquidity Events
Business Wire - Wed Apr 02, 7:02AM CDT
--5 Completed IPO Liquidity Events Q1 2014
Global RNA Interference (RNAi) Therapy Market Outlook 2018
M2 - Tue Apr 01, 6:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hthtnb/global_rna) has announced the addition of the "Global RNA Interference (RNAi) Therapy Market Outlook 2018" report to their offering. The popularity of RNAi technology has been increasing in recent times as is has become a major component of basic research, and in drug discovery. Over the years this technology has become an integral part of the process of determining the functions of gene, in analyzing pathways, and in the validation of the target both in academia and in industry. Since discovery, RNA interference is considered to be a turning point for molecular biology, it is most likely that this technology would grow in terms of its popularity and the significant research activity would be recorded in order to develop efficient and safe drug delivery mechanisms based on the RNAi therapy. Being a powerful tool for the study of functional genomics, this therapy provides enables the scientist to successfully silence any gene with artificial triggers of RNAi and utilizing the cellular machinery for efficient targeting of complementary transcripts. There are specific strategic reasons for the pharmaceutical industry to take interest in developing RNAi-based therapeutics. With the existing product pipelines exhausting for the big pharma companies, they are currently looking into RNAi therapeutics as potential fields which would enable the pipelines to be filled. Additionally, these companies have identified RNAi therapeutics to have the capability to target those diseases which are considered to be undruggable by small-molecule compounds or biologics. Thus, by investing in RNAi therapeutics at an early stage, the pharma companies would be able to build a strong foothold and have a commanding position in the market once these RNAi-based drugs reached the market. The RNAi therapy market, in the future years is likely to witness an increased level of activity in terms of RNAI technology development, specifically in the space of drug delivery. Though the main concept and clinical results behind RNAi are compelling, the pharma companies are still working towards identifying some new ideas which have great opportunity to grow. With human proof of concept demonstrated, it is most likely that the RNAi companies would reformulate new delivery technology and enjoy the benefits. Global RNAi Therapy Report Findings: - Number of RNAi Based Drugs in Clinical Trials: 151 - Highest RNAi Clinical Trial in Preclinical Phase - Oncology Dominating the RNAi Based Drugs Clinical Trial Process - US Dominates RNAi Market & Clinical Trial Landscape Key Topics Covered: 1. Introduction to RNA Interference (RNAi) Therapy 2. Benefits of RNA Interference (RNAi) Therapy 3. RNA Interference (RNAi) Drug Delivery Mechanics 4. Global RNA Interference (RNAi) Therapy Market Overview 5. Global RNA Interference (RNAi) Market Dynamics 6. RNAi Clinical Pipeline by Phase, Indication & Country 7. Suspended & Discontinued RNAi Profiles 8. Competitive Landscape Companies Mentioned - Arrowhead Research - Alnylam Pharmaceuticals - Benitec Biopharma - Dicerna Pharmaceuticals - InteRNA Technologies - Isis Pharmaceuticals - RXi Pharmaceuticals - Santaris Pharma - Silence Therapeutics - Tekmira Pharmaceuticals Corporation For more information visit http://www.researchandmarkets.com/research/hthtnb/global_rna
Dicerna Announces Fourth Quarter and Full Year 2013 Financial and Operational Results
Business Wire - Thu Mar 27, 3:01PM CDT
---Management to Host Conference Call at 4:30 PM ET-
The NASDAQ Stock Market Leads U.S. Exchanges for IPOs in Q1 2014
GlobeNewswire - Thu Mar 27, 7:50AM CDT
74 New U.S. Listings Including 45 IPOs
Dicerna to Present at Future Leaders in the Biotech Industry Conference on March 28, 2014
Business Wire - Tue Mar 25, 3:05PM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that Douglas M. Fambrough, PhD, the Company's President and CEO, is scheduled to present at the 21st Annual Future Leaders in the Biotech Industry conference on Friday, March 28, 2014 at 2:00 PM ET in New York, NY.
Dicerna to Announce Fourth Quarter 2013 Financial Results and Host Conference Call on March 27, 2014
Business Wire - Mon Mar 24, 3:41PM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, will report its fourth quarter 2013 financial results on March 27, 2014. Dicerna will host a conference call and live audio webcast on March 27, 2014 at 4:30 p.m. (ET) to discuss the Company's financial results and provide a general business update.
King Digital, CBS Outdoor Among 10 IPOs Set This Week
at Investor's Business Daily - Mon Mar 24, 3:10PM CDT
King Digital Entertainment leads a slate of 10 IPOs planned for this week, raising the total for the year to 79, up 77% from the year-earlier period. "Candy Crush Saga" developer King Digital is set to start trading on Wednesday. It plans to raise...
Biotechs Tripling at IPO! Sign of Biotech Bubble?
Brian Orelli, The Motley Fool - Motley Fool - Thu Mar 13, 6:24PM CDT
The proverbial biotech IPO window has been open for some time now, but it appears to have grown to the size of an airplane hangar door, allowing almost any biotech to go public at astonishingly high valuations. Ultragenyx Pharmaceutical doubled...
Dicerna to Present at Two Upcoming Conferences
Business Wire - Thu Mar 06, 8:01AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ RNA), a leader in the development of RNAi-based therapeutics, today announced that members of the management team will present at two upcoming conferences:
Dicerna to Present at 2014 AsiaTIDES Conference
Business Wire - Mon Feb 24, 8:04AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ RNA), a leader in the development of RNAi-based therapeutics, today announced that Bob D Brown, PhD, the Company's Chief Scientific Officer and SVP, is scheduled to participate in the 2014 AsiaTIDES Conference being held in Tokyo, Japan February 25-27, 2014. Dr. Brown will chair the main conference plenary session of keynote presentations addressing drug delivery systems for peptides and oligonucleotides; give a presentation titled, "Physical and Chemical Characterization of LNP Formulations of Oligonucleotides vs. Biological Activities;" and participate as a panel member discussing delivery approaches and challenges on Thursday, February 27, 2014.
Global RNAi Drug Delivery Market 2014-2018: Read What's Trending
M2 - Wed Feb 19, 12:15PM CST
Research and Markets (http://www.researchandmarkets.com/research/kv93pj/global_rnai_drug) has announced the addition of the "Global RNAi Drug Delivery Market 2014-2018" report to their offering. The analysts forecast the Global RNAi Drug Delivery market to grow at a CAGR of 21.80 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase in RNA therapeutic development. The Global RNAi Drug Delivery market has also been witnessing some key technological advancements. However, the targeted delivery of RNA molecules is expected to pose a challenge to the growth of this market. Key vendors dominating this space are Alnylam Pharmaceuticals Inc., Isis Pharmaceuticals, Inc.,Merck & Co. Inc., and Tekmira Pharmaceuticals Corp. Other vendors mentioned in the report are Access Pharmaceuticals Inc., Calondo Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Marina Biotech Inc., PhaseRx Inc., Quark Pharmaceuticals Inc., RXi Pharmaceuticals Corp., Silence Therapeutics plc, Sirnaomics Inc., Tacere Therapeutics Inc., and Traversa Therapeutics Inc. Commenting on the report, an analyst from the team said: Major advances in RNAi drug delivery are aimed at developing better delivery agents with excellent efficacy and the ability to target specific cells. For example, Bio-Path Holdings Inc. developed systemic delivery of antisense, small interfering RNA, and hydrophobic small molecules for treatment of various diseases using its neutral lipid drug delivery technology (neutral liposome). Similarly, Inovio's skin electroporation technology was used for the successful delivery of small interfering RNA molecules to skin in animal studies. Thus, technological innovations would further contribute to the growth of the Global RNAi Drug Delivery market. According to the report, one of the major drivers in this market is the increase in RNA therapeutic development. Therapeutic benefits greatly depend on the efficiency of the RNA delivery to specific diseased cells. This factor is the key to the development of RNAi drug delivery technologies and the market associated with it. For more information visit http://www.researchandmarkets.com/research/kv..._rnai_drug About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Dicerna to Present at 2014 Leerink Global Healthcare Conference on February 13th
Business Wire - Fri Feb 07, 8:05AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that Douglas M. Fambrough, PhD, the Company's President and CEO, is scheduled to present at the 2014 Leerink Global Healthcare Conference on Thursday, February 13, 2014 at 1:00 PM ET in New York, NY.
Dicerna Announces Participation in Panel on RNAi Therapeutics at 16th Annual BIO CEO and Investor Conference on February 10th
Business Wire - Wed Feb 05, 8:05AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ RNA), a leader in the development of RNAi-based therapeutics, today announced its participation in a panel discussion on RNAi therapeutics at the 16th Annual BIO CEO & Investor Conference. Douglas M. Fambrough, PhD, the company's President and CEO, is scheduled to take part in a Therapeutic Workshop entitled: "Delivering the [RNAi] Goods" to be held on Monday, February 10th, at 10:30 a.m. Eastern Standard Time.
Form 4: Update Filing for Dicerna Pharmaceuticals Inc (DRNA)
Vickers Stock Research - Wed Feb 05, 5:57AM CST
Mt. Laurel, NJ - February 5, 2013 - PHH Corporation (NYSE: PHH) ("PHH" or the "Company"
announced today that Kathryn M. Ruggieri has been named Senior Vice President and Chief Human Resources Officer. Ruggieri has served as Interim Chief Human Resources Officer since September 2012.
Dicerna Announces Closing of Initial Public Offering and Exercise of Option to Purchase Additional Shares
Business Wire - Tue Feb 04, 3:15PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) today announced the closing of its initial public offering of 6,900,000 shares of common stock, including 900,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, at a public offering price of $15.00 per share, before underwriting discounts. The aggregate net proceeds to Dicerna, after deducting underwriting discounts and commissions and estimated offering expenses, will be approximately $92.9 million.
Dicerna Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Business Wire - Fri Apr 18, 3:15PM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that it granted stock options to Pankaj Bhargava, M.D., the Company's chief medical officer, on April 16, 2014, including a stock option to purchase 246,406 shares of common stock of the Company outside of the Company's stockholder approved equity incentive plan. The grant of this stock option was approved by the compensation committee of the board of directors on April 16, 2014 as an inducement material to Dr. Bhargava entering into employment with the Company in reliance on NASDAQ Listing Rule 5635(c)(4). Dr. Bhargava joined the Company as chief medical officer on March 31, 2014. The stock option has an exercise price per share of $16.30, the closing price per share of Company's common stock as reported by NASDAQ on April 16, 2014 and is scheduled to vest over a four-year period, subject to his continued service with the Company. Dr. Bhargava's other compensation information is summarized in a Current Report on Form 8-K previously filed by the Company with the Securities and Exchange Commission.
Dicerna Pharmaceuticals Initiates Phase 1 Study of DCR-MYC in Patients with Solid Tumors and Hematological Malignancies
Business Wire - Wed Apr 16, 3:15PM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced the initiation of a Phase 1 dose-escalating clinical study of DCR-MYC, (also known as DCR-M1711), in patients with solid tumors, multiple myeloma, or lymphoma. DCR-MYC, Dicerna's first drug candidate to enter clinical testing, is a Dicer Substrate siRNA (DsiRNA) that targets the driver oncogene MYC, which is central to the growth of many hematologic and solid tumor malignancies. Dicerna is investigating DCR-MYC in a variety of tumor types with the initial focus on hepatocellular carcinoma.
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Apr 05, 7:10AM CDT
Ugh, ugh, and ugh. Quite a few stocks got hit hard this week, but few like three especially unlucky health-care stocks. April Fools' Day is over, but shareholders of this week's big losers probably still feel like someone is pulling a prank on them....
Is Biotech in a Bubble? The Bear Case Explained
Chris Ahlstrand, The Motley Fool - Motley Fool - Fri Apr 04, 8:30AM CDT
The rumblings of a biotech bubble are getting louder as the Nasdaq Biotech Index has declined about 14% from its peak of $275.40 on February 25th. The recent volatility is a phenomenon that has not been seen in quite some time in the space. So is...
Dicerna Pharmaceuticals names Dr Pankaj Bhargava as CMO
M2 - Thu Apr 03, 5:02AM CDT
RNAi therapeutics company Dicerna Pharmaceuticals (NasdaqGS
RNA) disclosed on Wednesday the addition of Pankaj Bhargava MD, as its chief medical officer. Hercules Technology Growth Capital Announces Portfolio Update for Q1 2014; Quarter Marked By Continued Portfolio Diversity and Growth and Significant Number of Liquidity Events
Business Wire - Wed Apr 02, 7:02AM CDT
--5 Completed IPO Liquidity Events Q1 2014
Global RNA Interference (RNAi) Therapy Market Outlook 2018
M2 - Tue Apr 01, 6:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hthtnb/global_rna) has announced the addition of the "Global RNA Interference (RNAi) Therapy Market Outlook 2018" report to their offering. The popularity of RNAi technology has been increasing in recent times as is has become a major component of basic research, and in drug discovery. Over the years this technology has become an integral part of the process of determining the functions of gene, in analyzing pathways, and in the validation of the target both in academia and in industry. Since discovery, RNA interference is considered to be a turning point for molecular biology, it is most likely that this technology would grow in terms of its popularity and the significant research activity would be recorded in order to develop efficient and safe drug delivery mechanisms based on the RNAi therapy. Being a powerful tool for the study of functional genomics, this therapy provides enables the scientist to successfully silence any gene with artificial triggers of RNAi and utilizing the cellular machinery for efficient targeting of complementary transcripts. There are specific strategic reasons for the pharmaceutical industry to take interest in developing RNAi-based therapeutics. With the existing product pipelines exhausting for the big pharma companies, they are currently looking into RNAi therapeutics as potential fields which would enable the pipelines to be filled. Additionally, these companies have identified RNAi therapeutics to have the capability to target those diseases which are considered to be undruggable by small-molecule compounds or biologics. Thus, by investing in RNAi therapeutics at an early stage, the pharma companies would be able to build a strong foothold and have a commanding position in the market once these RNAi-based drugs reached the market. The RNAi therapy market, in the future years is likely to witness an increased level of activity in terms of RNAI technology development, specifically in the space of drug delivery. Though the main concept and clinical results behind RNAi are compelling, the pharma companies are still working towards identifying some new ideas which have great opportunity to grow. With human proof of concept demonstrated, it is most likely that the RNAi companies would reformulate new delivery technology and enjoy the benefits. Global RNAi Therapy Report Findings: - Number of RNAi Based Drugs in Clinical Trials: 151 - Highest RNAi Clinical Trial in Preclinical Phase - Oncology Dominating the RNAi Based Drugs Clinical Trial Process - US Dominates RNAi Market & Clinical Trial Landscape Key Topics Covered: 1. Introduction to RNA Interference (RNAi) Therapy 2. Benefits of RNA Interference (RNAi) Therapy 3. RNA Interference (RNAi) Drug Delivery Mechanics 4. Global RNA Interference (RNAi) Therapy Market Overview 5. Global RNA Interference (RNAi) Market Dynamics 6. RNAi Clinical Pipeline by Phase, Indication & Country 7. Suspended & Discontinued RNAi Profiles 8. Competitive Landscape Companies Mentioned - Arrowhead Research - Alnylam Pharmaceuticals - Benitec Biopharma - Dicerna Pharmaceuticals - InteRNA Technologies - Isis Pharmaceuticals - RXi Pharmaceuticals - Santaris Pharma - Silence Therapeutics - Tekmira Pharmaceuticals Corporation For more information visit http://www.researchandmarkets.com/research/hthtnb/global_rna
Dicerna Announces Fourth Quarter and Full Year 2013 Financial and Operational Results
Business Wire - Thu Mar 27, 3:01PM CDT
---Management to Host Conference Call at 4:30 PM ET-
The NASDAQ Stock Market Leads U.S. Exchanges for IPOs in Q1 2014
GlobeNewswire - Thu Mar 27, 7:50AM CDT
74 New U.S. Listings Including 45 IPOs
Dicerna to Present at Future Leaders in the Biotech Industry Conference on March 28, 2014
Business Wire - Tue Mar 25, 3:05PM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that Douglas M. Fambrough, PhD, the Company's President and CEO, is scheduled to present at the 21st Annual Future Leaders in the Biotech Industry conference on Friday, March 28, 2014 at 2:00 PM ET in New York, NY.
Dicerna to Announce Fourth Quarter 2013 Financial Results and Host Conference Call on March 27, 2014
Business Wire - Mon Mar 24, 3:41PM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, will report its fourth quarter 2013 financial results on March 27, 2014. Dicerna will host a conference call and live audio webcast on March 27, 2014 at 4:30 p.m. (ET) to discuss the Company's financial results and provide a general business update.
King Digital, CBS Outdoor Among 10 IPOs Set This Week
at Investor's Business Daily - Mon Mar 24, 3:10PM CDT
King Digital Entertainment leads a slate of 10 IPOs planned for this week, raising the total for the year to 79, up 77% from the year-earlier period. "Candy Crush Saga" developer King Digital is set to start trading on Wednesday. It plans to raise...
Biotechs Tripling at IPO! Sign of Biotech Bubble?
Brian Orelli, The Motley Fool - Motley Fool - Thu Mar 13, 6:24PM CDT
The proverbial biotech IPO window has been open for some time now, but it appears to have grown to the size of an airplane hangar door, allowing almost any biotech to go public at astonishingly high valuations. Ultragenyx Pharmaceutical doubled...
Dicerna to Present at Two Upcoming Conferences
Business Wire - Thu Mar 06, 8:01AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ
RNA), a leader in the development of RNAi-based therapeutics, today announced that members of the management team will present at two upcoming conferences: Dicerna to Present at 2014 AsiaTIDES Conference
Business Wire - Mon Feb 24, 8:04AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ
RNA), a leader in the development of RNAi-based therapeutics, today announced that Bob D Brown, PhD, the Company's Chief Scientific Officer and SVP, is scheduled to participate in the 2014 AsiaTIDES Conference being held in Tokyo, Japan February 25-27, 2014. Dr. Brown will chair the main conference plenary session of keynote presentations addressing drug delivery systems for peptides and oligonucleotides; give a presentation titled, "Physical and Chemical Characterization of LNP Formulations of Oligonucleotides vs. Biological Activities;" and participate as a panel member discussing delivery approaches and challenges on Thursday, February 27, 2014. Global RNAi Drug Delivery Market 2014-2018: Read What's Trending
M2 - Wed Feb 19, 12:15PM CST
Research and Markets (http://www.researchandmarkets.com/research/kv93pj/global_rnai_drug) has announced the addition of the "Global RNAi Drug Delivery Market 2014-2018" report to their offering. The analysts forecast the Global RNAi Drug Delivery market to grow at a CAGR of 21.80 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase in RNA therapeutic development. The Global RNAi Drug Delivery market has also been witnessing some key technological advancements. However, the targeted delivery of RNA molecules is expected to pose a challenge to the growth of this market. Key vendors dominating this space are Alnylam Pharmaceuticals Inc., Isis Pharmaceuticals, Inc.,Merck & Co. Inc., and Tekmira Pharmaceuticals Corp. Other vendors mentioned in the report are Access Pharmaceuticals Inc., Calondo Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Marina Biotech Inc., PhaseRx Inc., Quark Pharmaceuticals Inc., RXi Pharmaceuticals Corp., Silence Therapeutics plc, Sirnaomics Inc., Tacere Therapeutics Inc., and Traversa Therapeutics Inc. Commenting on the report, an analyst from the team said: Major advances in RNAi drug delivery are aimed at developing better delivery agents with excellent efficacy and the ability to target specific cells. For example, Bio-Path Holdings Inc. developed systemic delivery of antisense, small interfering RNA, and hydrophobic small molecules for treatment of various diseases using its neutral lipid drug delivery technology (neutral liposome). Similarly, Inovio's skin electroporation technology was used for the successful delivery of small interfering RNA molecules to skin in animal studies. Thus, technological innovations would further contribute to the growth of the Global RNAi Drug Delivery market. According to the report, one of the major drivers in this market is the increase in RNA therapeutic development. Therapeutic benefits greatly depend on the efficiency of the RNA delivery to specific diseased cells. This factor is the key to the development of RNAi drug delivery technologies and the market associated with it. For more information visit http://www.researchandmarkets.com/research/kv..._rnai_drug About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Dicerna to Present at 2014 Leerink Global Healthcare Conference on February 13th
Business Wire - Fri Feb 07, 8:05AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that Douglas M. Fambrough, PhD, the Company's President and CEO, is scheduled to present at the 2014 Leerink Global Healthcare Conference on Thursday, February 13, 2014 at 1:00 PM ET in New York, NY.
Dicerna Announces Participation in Panel on RNAi Therapeutics at 16th Annual BIO CEO and Investor Conference on February 10th
Business Wire - Wed Feb 05, 8:05AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ
RNA), a leader in the development of RNAi-based therapeutics, today announced its participation in a panel discussion on RNAi therapeutics at the 16th Annual BIO CEO & Investor Conference. Douglas M. Fambrough, PhD, the company's President and CEO, is scheduled to take part in a Therapeutic Workshop entitled: "Delivering the [RNAi] Goods" to be held on Monday, February 10th, at 10:30 a.m. Eastern Standard Time. Form 4: Update Filing for Dicerna Pharmaceuticals Inc (DRNA)
Vickers Stock Research - Wed Feb 05, 5:57AM CST
Mt. Laurel, NJ - February 5, 2013 - PHH Corporation (NYSE: PHH) ("PHH" or the "Company"
announced today that Kathryn M. Ruggieri has been named Senior Vice President and Chief Human Resources Officer. Ruggieri has served as Interim Chief Human Resources Officer since September 2012. Dicerna Announces Closing of Initial Public Offering and Exercise of Option to Purchase Additional Shares
Business Wire - Tue Feb 04, 3:15PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) today announced the closing of its initial public offering of 6,900,000 shares of common stock, including 900,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, at a public offering price of $15.00 per share, before underwriting discounts. The aggregate net proceeds to Dicerna, after deducting underwriting discounts and commissions and estimated offering expenses, will be approximately $92.9 million.
